Home › Compare › CTVIF vs ABBV
CTVIF yields 23.97% · ABBV yields 3.06%● Live data
📍 CTVIF pulled ahead of the other in Year 1
Combined, CTVIF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CTVIF + ABBV for your $10,000?
China Travel International Investment Hong Kong Limited, an investment holding company, provides travel and tourism services. Its Tourist Attraction and Related Operations segment operates theme parks, scenic spots, cable car systems, skiing facilities, hot spring resorts, and other resorts, as well as engages in arts performance and tourism property development activities in Mainland China. The company's Travel Agency, Travel Document, and Related Operations segment provides travel agency, travel document, and related services in Hong Kong, Mainland China, South East Asia, Oceania, the United States, and countries in the European Union. Its Hotel Operations segment offers hotel accommodation, and food and beverage services in Hong Kong, Macau, and Mainland China. The company's Passenger Transportation Operations segment provides cross-border transportation services to individuals travelling between Hong Kong, Macau, and Mainland China; and vehicle and vessel rental and charter operations in Hong Kong, Macau, and Mainland China. It also operates golf clubs; trades in computer equipment and provides computer services; and offers travel and air ticketing agency, entry permit handling agency, fuel supply, ship repairing, and logistics and courier services. In addition, the company is involved in property investment; software system development; and shipping and shipping management activities, as well as conference and exhibition operations. The company was incorporated in 1992 and is based in Central, Hong Kong. China Travel International Investment Hong Kong Limited is a subsidiary of China Travel Service (Holdings) Hong Kong Limited.
Full CTVIF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.